Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
AssigneeAbGenomics Cooperatief U.A.
InventorsRong-Hwa Lin, Chung-Hsiun Wu, Pei-Ling Hsu
Life of this patent
Estimating the term…
Abstract
Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as autoimmune diseases, transplant rejection, and allergic diseases.
Claims18
A method of reducing an excessive or unwanted T cell-mediated immune response in an individual diagnosed as having a condition characterized by an excessive or unwanted T cell-mediated immune response, the method comprising:
- selecting an anti-PSGL-1 antibody based on its ability both to bind specifically to P-Selectin Glycoprotein Ligand-1 (PSGL-1) on the surface of an activated T cell and to induce apoptosis of the activated T cell;
- and
- administering to the individual a composition comprising an effective amount of the selected apoptosis-inducing anti-PSGL-1 antibody to reduce the excessive or unwanted T cell-mediated immune response in the individual.
A method of inducing the death of an activated T cell or a natural killer (NK) cell, the method comprising:
- selecting an anti-PSGL-1 antibody based on its ability both to bind specifically to P-Selectin Glycoprotein Ligand-1 (PSGL-1) on the surface of an activated T cell and to induce apoptosis of the activated T cell;
- providing an activated T cell or NK cell expressing PSGL-1 on its cell surface;
- and
- contacting the activated T cell or NK cell with an effective amount of the selected apoptosis-inducing anti-PSGL-1 antibody to induce apoptosis of the activated T cell or NK cell.
Dependencies are inferred from the claim text.